These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 27184622

  • 21. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M.
    Vaccine; 2013 Nov 12; 31(47):5572-8. PubMed ID: 24016810
    [Abstract] [Full Text] [Related]

  • 22. The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.
    de Boer PT, Kelso JK, Halder N, Nguyen TP, Moyes J, Cohen C, Barr IG, Postma MJ, Milne GJ.
    Vaccine; 2018 Feb 08; 36(7):997-1007. PubMed ID: 29373192
    [Abstract] [Full Text] [Related]

  • 23. A systematic review of the health economic consequences of quadrivalent influenza vaccination.
    de Boer PT, van Maanen BM, Damm O, Ultsch B, Dolk FCK, Crépey P, Pitman R, Wilschut JC, Postma MJ.
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun 08; 17(3):249-265. PubMed ID: 28613092
    [Abstract] [Full Text] [Related]

  • 24. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
    Scholz SM, Weidemann F, Damm O, Ultsch B, Greiner W, Wichmann O.
    Value Health; 2021 Jan 08; 24(1):32-40. PubMed ID: 33431151
    [Abstract] [Full Text] [Related]

  • 25. Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability.
    Hendriks J, Hutubessy RCW, Grohmann G, Torelli G, Friede M, Kieny MP.
    Vaccine; 2018 Jun 27; 36(28):3993-3997. PubMed ID: 29866617
    [Abstract] [Full Text] [Related]

  • 26. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M.
    Pediatr Infect Dis J; 2014 Dec 27; 33(12):1262-9. PubMed ID: 25386965
    [Abstract] [Full Text] [Related]

  • 27. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China].
    Yan H, Yang J, Chen ZY, Gong H, Zhong GJ, Yu HJ.
    Zhonghua Yi Xue Za Zhi; 2021 Aug 10; 101(30):2405-2412. PubMed ID: 34404135
    [Abstract] [Full Text] [Related]

  • 28. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
    Nagy L, Heikkinen T, Sackeyfio A, Pitman R.
    Pharmacoeconomics; 2016 Sep 10; 34(9):939-51. PubMed ID: 27423657
    [Abstract] [Full Text] [Related]

  • 29. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.
    Beran J, Peeters M, Dewé W, Raupachová J, Hobzová L, Devaster JM.
    BMC Infect Dis; 2013 May 20; 13():224. PubMed ID: 23688546
    [Abstract] [Full Text] [Related]

  • 30. Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.
    Van Bellinghen LA, Marijam A, Tannus Branco de Araujo G, Gomez J, Van Vlaenderen I.
    Braz J Infect Dis; 2018 May 20; 22(1):1-10. PubMed ID: 29352897
    [Abstract] [Full Text] [Related]

  • 31. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
    Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK.
    Vaccine; 2014 Mar 14; 32(13):1480-7. PubMed ID: 24486352
    [Abstract] [Full Text] [Related]

  • 32. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.
    Bianculli PM, Bellier L, Mangado IO, Pérez CG, Mieres G, Lazarov L, Petitjean A, Dibarboure H, Lopez JG.
    Hum Vaccin Immunother; 2022 Nov 30; 18(5):2050653. PubMed ID: 35344679
    [Abstract] [Full Text] [Related]

  • 33. The economic value of a quadrivalent versus trivalent influenza vaccine.
    Lee BY, Bartsch SM, Willig AM.
    Vaccine; 2012 Dec 14; 30(52):7443-6. PubMed ID: 23084849
    [Abstract] [Full Text] [Related]

  • 34. Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea.
    Yun JW, Choi MJ, Shin GS, Lim JO, Noh JY, Kim YK, Song JY, Kim WJ, Choi SE, Cheong HJ.
    PLoS One; 2019 Dec 14; 14(1):e0209643. PubMed ID: 30682030
    [Abstract] [Full Text] [Related]

  • 35. Introduction of a quadrivalent influenza vaccine in Italy: a budget impact analysis.
    Pitrelli A.
    J Prev Med Hyg; 2016 Dec 14; 57(1):E34-40. PubMed ID: 27346938
    [Abstract] [Full Text] [Related]

  • 36. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model.
    Van Bellinghen LA, Meier G, Van Vlaenderen I.
    PLoS One; 2014 Dec 14; 9(6):e98437. PubMed ID: 24905235
    [Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
    Bellier L, Petitjean A, Sarazu T, Tresierra J, Lopez JG.
    Vaccine; 2021 Jul 05; 39(30):4144-4152. PubMed ID: 34130885
    [Abstract] [Full Text] [Related]

  • 38. Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.
    Thommes EW, Kruse M, Kohli M, Sharma R, Noorduyn SG.
    Hum Vaccin Immunother; 2017 Apr 03; 13(4):867-876. PubMed ID: 27858509
    [Abstract] [Full Text] [Related]

  • 39. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
    Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ.
    Vaccine; 2008 Jun 02; 26(23):2841-8. PubMed ID: 18462851
    [Abstract] [Full Text] [Related]

  • 40. Simulation studies to assess the long-term effects of Japan's change from trivalent to quadrivalent influenza vaccination.
    Tsuzuki S, Schwehm M, Eichner M.
    Vaccine; 2018 Jan 29; 36(5):624-630. PubMed ID: 29292176
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.